SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Nucl Med. 2008; 49 (Supplement 1):283P
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Adler, L.
Right arrow Articles by Joshi, A.
PubMed
Right arrow Articles by Adler, L.
Right arrow Articles by Joshi, A.

Radiopharmaceutical Chemistry: Dosimetry/Radiobiology

Dosimetry/Radiobiology Posters

Radiation dosimetry of F18-AV-45 measured by PET/CT in humans

Lee Adler1, John Wolodzko2, Michael Stabin3, Trish McNelis1, Linda Gammage1 and Abhinay Joshi2

1 Adler Institute for Advanced Imaging, Jenkintown, Pennsylvania; ; 2 Avid Radiopharmaceuticals, Inc., Philadelphia, Pennsylvania; ; 3 Radiology, Vanderbilt University, Nashville, Tennessee

1211

Objectives: To determine the Radiation Dosimetry of (E)-4-(2-(6-(2-(2-(2-[F18]fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine (F18-AV-45), a novel fluorinated radioligand with an affinity for beta amyloid plaque being developed as a noninvasive biomarker for Alzheimer's Disease.

Methods: Following approval of community IRB & Radiation Safety Committees, 9 normal volunteers (3M, 6F), ages 45-73 were studied. After informed consent, all subjects received routine testing and monitoring for a Phase I clinical investigation of a novel radiopharmaceutical. Following administration of 359 to 443 MBq F18-AV-45 iv, subjects received up to 6 CT and 11 PET scans (vertex to thighs) with a Biograph 40 TruePoint PET/CT scanner (Siemens Medical Solutions USA, Inc) over 7 hours. Iterative reconstruction (2i/8s/7mm/1282 matrix) was performed with attenuation, scatter and randoms correction. Regions of interest were drawn for all organs with visibly increased tracer localization on PET to measure average uncorrected activity at the time of each scan. Time integrals of organ activity were entered into the OLINDA/EXM code, using the adult male model. Bowel activity was used to estimate biliary excretion, using the kinetic model for the GI tract in OLINDA/EXM.

Results: Liver, gallbladder, small intestine and upper large intestine receive 0.06-0.15 mSv/MBq. Other organs receive 0.005-0.03 mSv/MBq.

Conclusions: The effective dose is 0.016±.003 mSv/MBq which compares favorably with the effective dose for FDG of 0.023 mSv/MBq. The data were reasonably consistent between subjects. The gall bladder is the critical organ with a dose of 0.15±.08 mSv/MBq.

Research Support: This investigation was supported by a grant from Avid Radiopharmaceuticals, Inc.





Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Adler, L.
Right arrow Articles by Joshi, A.
PubMed
Right arrow Articles by Adler, L.
Right arrow Articles by Joshi, A.